Nearly half of individuals consuming alcohol at baseline reduced their alcohol consumption following the initiation of AOMs. Potential mechanisms for this association include pharmacological effects, such as the ability of naltrexone to reduce alcohol cravings, as well as the impact of GLP-1 RAs on attenuating the rewarding effects of alcohol use.